Kathy Dong
Directeur Général chez Electra Therapeutics, Inc.
Profil
Kathy Dong is currently the President & Chief Executive Officer at Electra Therapeutics, Inc. and also serves as a Director at Neuron23, Inc. Previously, she worked as the Chief Operating Officer at Star Therapeutics, Inc. Dr. Dong holds an MBA and a doctorate from the University of New Mexico School of Medicine.
Postes actifs de Kathy Dong
| Sociétés | Poste | Début |
|---|---|---|
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Directeur/Membre du Conseil | 14/06/2022 |
Electra Therapeutics, Inc.
 Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Directeur Général | 11/12/2023 |
Anciens postes connus de Kathy Dong
| Sociétés | Poste | Fin |
|---|---|---|
Star Therapeutics, Inc.
 Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Directeur des opérations | - |
Formation de Kathy Dong
| University of New Mexico School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Star Therapeutics, Inc.
Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Health Technology |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Commercial Services |
Electra Therapeutics, Inc.
Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Health Technology |